ONO PHARMA partners with Bristol Myers SquibbBristol-Myers Squibb ( BMY ), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients with micro-satellite s
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.35 USD
885.03 M USD
3.48 B USD
About ONO PHARMACEUTICAL CO
Sector
Industry
CEO
Gyo Sagara
Website
Headquarters
Osaka
Founded
1947
FIGI
BBG000G1QMG5
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
ONO PHARMA partners with Bristol Myers SquibbTODAY'S ANNOUNCEMENT
Bristol-Myers Squibb (BMY), Bayer and Ono Pharmaceutical (OPHLY) have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo in patients wi
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.